Key result
Tumor cell-specific gene expression profiles and mutational status have superior potential as predictors of venous thromboembolism in cancer patients compared to classical parameters.
Why the study?
Do tumor cell-specific gene expression profiles better predict cancer-associated thrombosis than classical risk factors in cancer patients?
Do tumor cell-specific gene expression profiles better predict cancer-associated thrombosis than classical risk factors in cancer patients?
Tumor-specific genetic profiling may offer a more accurate method for predicting venous thromboembolism risk in cancer patients than traditional biomarkers.
No takes yet. Share an insight, caveat, or question.
May refine cancer VTE risk stratification; leaves open prospective validation against classical scores.
Ünlü et al. (2018) conducted a review in Cancer-associated thrombosis. Tumor cell-specific gene expression profiles and mutational status vs. Classical risk factors was evaluated on Venous thromboembolism (VTE). Tumor cell-specific gene expression profiles and mutational status have superior potential as predictors of venous thromboembolism in cancer patients compared to classical parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: